Drug Shortage Report for JEVTANA

Last updated on 2019-07-19 History
Report ID 87765
Drug Identification Number 02369524
Brand name JEVTANA
Common or Proper name Jevtana
Company Name SANOFI-AVENTIS CANADA INC
Market Status CANCELLED POST MARKET
Active Ingredient(s) CABAZITAXEL
Strength(s) 40MG
Dosage form(s) SOLUTION
Route of administration INTRAVENOUS
Packaging size 1
ATC code L01CD
ATC description PLANT ALKALOIDS AND OTHER NATURAL PRODUCTS
Reason for shortage Other (Please describe in comments)
Anticipated start date 2019-07-27
Actual start date
Estimated end date 2019-08-30
Actual end date 2019-07-18
Shortage status Avoided shortage
Updated date 2019-07-19
Company comments Temporary supply delay. Allocation has been initiated based on historical sales. It is recommended that no new treatment be initiated, to reserve the supplies to patients already under treatment. The availability date represents estimated availability at the main Sanofi warehouse. Availability dates at a customer’s usual distributor warehouse may vary. Pharmacies are invited to communicate with their preferred distributor to obtain the product availability date. Patients should validate the availability of the product with their respective pharmacy.
Health Canada comments
Tier 3 Status No
Company contact information email: CAINTERNET@sanofi.com Telephone: 1-800-265-7927

Version History

Click on "Compare" below to view the full report history and compare to other versions.

Version Number Date Updated Language
v4 2019-07-19 French Compare
v3 2019-07-19 English Compare
v2 2019-06-27 French Compare
v1 2019-06-27 English Compare

Showing 1 to 4 of 4